Last reviewed · How we verify
Meropenem 1000 mg
At a glance
| Generic name | Meropenem 1000 mg |
|---|---|
| Also known as | Meropenem 2000 mg |
| Sponsor | Hospital Universitari de Bellvitge |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever (PHASE4)
- Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis (PHASE2, PHASE3)
- A Pilot Study for Optimizing Meropenem Administration in the ICU (NA)
- A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (PHASE3)
- Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae (PHASE4)
- Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
- Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) (PHASE3)
- Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meropenem 1000 mg CI brief — competitive landscape report
- Meropenem 1000 mg updates RSS · CI watch RSS
- Hospital Universitari de Bellvitge portfolio CI